|
| | Publication Year | Title | Author(s) |
| 1 | 12-Dec-2013 | Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer. | Jonker, D J; Karapetis, C S; Harbison, C; O'Callaghan, Christopher J ; Tu, D; Simes, R J; Malone, D P; Langer, C; Tebbutt, Niall C ; Price, Timothy J; Shapiro, J; Siu, L L; Wong, R P W; Bjarnason, G; Moore, M J; Zalcberg, John R; Khambata-Ford, S |
| 2 | 3-Dec-2013 | Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. | Greenhalf, William; Ghaneh, Paula; Neoptolemos, John P; Palmer, Daniel H; Cox, Trevor F; Lamb, Richard F; Garner, Elizabeth; Campbell, Fiona; Mackey, John R; Costello, Eithne; Moore, Malcolm J; Valle, Juan W; McDonald, Alexander C; Carter, Ross; Tebbutt, Niall C ; Goldstein, David B; Shannon, Jennifer; Dervenis, Christos; Glimelius, Bengt; Deakin, Mark; Charnley, Richard M; Lacaine, François; Scarfe, Andrew G; Middleton, Mark R; Anthoney, Alan; Halloran, Christopher M; Mayerle, Julia; Oláh, Attila; Jackson, Richard; Rawcliffe, Charlotte L; Scarpa, Aldo; Bassi, Claudio; Büchler, Markus W |
| 3 | 8-Nov-2013 | The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: results from the Australasian phase III MAX study. | Carter, Hannah E; Zannino, Diana; John Simes, R; Schofield, Deborah J; Howard, Kirsten; Zalcberg, John R; Price, Timothy J; Tebbutt, Niall C |
| 4 | 16-Sep-2013 | Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. | Ohtsu, Atsushi; Ajani, Jaffer A; Bai, Yu-Xian; Bang, Yung-Jue; Chung, Hyun-Cheol; Pan, Hong-Ming; Sahmoud, Tarek; Shen, Lin; Yeh, Kun-Huei; Chin, Keisho; Muro, Kei; Kim, Yeul Hong; Ferry, David; Tebbutt, Niall C ; Al-Batran, Salah-Eddin; Smith, Heind; Costantini, Chiara; Rizvi, Syed; Lebwohl, David; Van Cutsem, Eric |
| 5 | 16-Nov-2012 | Biliary stenting versus surgical bypass for palliation of periampullary malignancy. | Nikfarjam, Mehrdad ; Hadj, Andrew K; Muralidharan, Vijayaragavan ; Tebbutt, Niall C ; Fink, Michael A ; Jones, Robert M ; Starkey, Graham; Vaughan, Rhys B ; Marshall, Alexander W; Christophi, Christopher |
| 6 | 27-Jan-2011 | Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. | Tebbutt, Niall C ; Murphy, F; Zannino, D; Wilson, K; Cummins, M M; Abdi, E; Strickland, A H; Lowenthal, R M; Marx, G; Karapetis, C; Shannon, J; Goldstein, David B; Nayagam, S S; Blum, R; Chantrill, L; Simes, R J; Price, Timothy J |
| 7 | 1-Jun-2010 | Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. | Tebbutt, Niall C ; Wilson, Kate; Gebski, Val J; Cummins, Michelle M; Zannino, Diana; van Hazel, Guy A; Robinson, Bridget; Broad, Adam; Ganju, Vinod; Ackland, Stephen P; Forgeson, Garry; Cunningham, David; Saunders, Mark P; Stockler, Martin R; Chua, Yujo; Zalcberg, John R; Simes, R John; Price, Timothy J |
| 8 | 12-Jan-2010 | Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. | Tebbutt, Niall C ; Cummins, M M; Sourjina, T; Strickland, A; Van Hazel, G; Ganju, V; Gibbs, D; Stockler, M; Gebski, V; Zalcberg, John R |
| 9 | 13-Oct-2009 | Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers. | Herbertson, Rebecca A; Tebbutt, Niall C ; Lee, Fook-Thean; MacFarlane, David J; Chappell, Bridget; Micallef, Noel; Lee, Sze-Ting; Saunder, Timothy; Hopkins, Wendie; Smyth, Fiona E; Wyld, David K; Bellen, John; Sonnichsen, Daryl S; Brechbiel, Martin W; Murone, Carmel ; Scott, Andrew M |
| 10 | 1-Jun-2007 | A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen. | Scott, Andrew M ; Tebbutt, Niall C ; Lee, Fook-Thean; Cavicchiolo, Tina; Liu, Zhanqi; Gill, Sanjeev; Poon, Aurora M T ; Hopkins, Wendie; Smyth, Fiona E; Murone, Carmel ; MacGregor, Duncan; Papenfuss, Anthony T; Chappell, Bridget; Saunder, Timothy H; Brechbiel, Martin W; Davis, Ian D; Murphy, Roger; Chong, Geoffrey ; Hoffman, Eric W; Old, Lloyd J |
| 11 | 13-Apr-2007 | The expanding role of PET technology in the management of patients with colorectal cancer. | Herbertson, R A; Lee, S T; Tebbutt, Niall C ; Scott, Andrew M |
| 12 | 6-Feb-2007 | Treatment of 5-fluorouracil refractory metastatic colorectal cancer: an Australian population-based analysis. | Damianovich, D; Adena, M; Tebbutt, Niall C |
| 13 | 17-Dec-2006 | Severe combined hyperlipidaemia and retinal lipid infiltration in a patient with Type 2 diabetes mellitus. | Davey, Rachel A; Tebbutt, Niall C ; Favaloro, Jenny M; O'neal, David N; Rae, Derek; Zajac, Jeffrey D ; Best, James D |
Loading...
2
0
20
0
false